In response to the latest analysis of the Women's Health Initiative randomized study of postmenopausal women taking hormone therapy, the American Congress of Obstetricians and Gynecologists adivsed ob/gyns to continue to counsel women who are considering hormone therapy for relief of menopausal symptoms to use the lowest effective dose for the shortest period of time.
In response to the latest analysis of the Women's Health Initiative (WHI) randomized study of postmenopausal women taking hormone therapy, the American Congress of Obstetricians and Gynecologists (ACOG) advised ob/gyns to continue to counsel women who are considering hormone therapy for relief of menopausal symptoms to use the lowest effective dose for the shortest period of time.1
The most recent study, by Chlebowski and colleagues, and published in the Journal of the American Medical Association (JAMA), found that women taking combined estrogen plus progestin are at increased risk of invasive breast cancer, breast cancers presenting with positive lymph nodes, and breast cancer mortality.2 ACOG noted that while the absolute risk of breast cancer mortality is small, it is significantly increased in women taking combined estrogen plus daily progestin. It also observed that a 2004 WHI report in JAMA on the estrogen-alone component of hormone therapy found no increase in breast cancer risk among women with hysterectomy over an average of 7 years of randomized treatment.
1American Congress of Obstetricians and Gynecologists. The College responds to new report from the Women's Health Initiative regarding estrogen plus progestin hormone therapy and breast cancer. http://www.acog.org/from_home/misc/20101021WHIResponse.cfm/. Accessed December 3, 2010.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More